Try our mobile app

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

Published: 2023-09-21 05:00:00 ET
<<<  go to ARGX company page

  • VYVGARTis the first-and-only neonatal Fc receptor (FcRn) blocker authorized for salein Canada
  • Approval based on the positive Phase 3 ADAPTtrial (p